Quarterly report · Q2
4598.TEDINET S100S9OY
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Operating income | −¥593m | 2023-04-01 → 2023-09-30 | Standalone | Operating income |
| Operating income | −¥612m | 2022-04-01 → 2022-09-30 | Standalone | Operating income |
| Ordinary income | −¥599m | 2023-04-01 → 2023-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥621m | 2022-04-01 → 2022-09-30 | Standalone | Ordinary income |
| Profit before tax | −¥599m | 2023-04-01 → 2023-09-30 | Standalone | Income before income taxes |
| Profit before tax | −¥621m | 2022-04-01 → 2022-09-30 | Standalone | Income before income taxes |
| Net income | −¥600m | 2023-04-01 → 2023-09-30 | Standalone | Profit loss |
| Net income | −¥1.3bn | 2022-04-01 → 2023-03-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥623m | 2022-04-01 → 2022-09-30 | Standalone | Profit loss |
| Total assets | ¥491m | at 2023-09-30 | Standalone | Assets |
| Total assets | ¥907m | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥734m | at 2022-09-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥88m | at 2023-09-30 | Standalone | Liabilities |
| Total liabilities | ¥116m | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥403m | at 2023-09-30 | Standalone | Net assets |
| Net assets / equity | ¥791m | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥611m | at 2022-09-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥437m | at 2023-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥844m | at 2023-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥437m | at 2023-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥844m | at 2023-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥668m | at 2022-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2022-03-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥619m | 2023-04-01 → 2023-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.3bn | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥600m | 2022-04-01 → 2022-09-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | ¥918,000 | 2023-04-01 → 2023-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥326,000 | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥321,000 | 2022-04-01 → 2022-09-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥211m | 2023-04-01 → 2023-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥883m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥37,000 | 2022-04-01 → 2022-09-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-91.92 | 2023-04-01 → 2023-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-48.84 | 2023-07-01 → 2023-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-234.51 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-114.88 | 2022-04-01 → 2022-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-57.93 | 2022-07-01 → 2022-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 81.8% | at 2023-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.0% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.1% | at 2022-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 6,544,600 | at 2023-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 6,369,600 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,419,600 | at 2022-09-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 320
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYTDDuration_NonConsolidatedMember | 211138000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration_NonConsolidatedMember | -37000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration_NonConsolidatedMember | -37000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration_NonConsolidatedMember | 211138000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration_NonConsolidatedMember | 73000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration_NonConsolidatedMember | -538000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration_NonConsolidatedMember | -600785000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration_NonConsolidatedMember | -407529000 | JPY |
| Cash and cash equivalents | Prior2YearInstant_NonConsolidatedMember | 1268492000 | JPY |
| Cash and cash equivalents | Prior1YearInstant_NonConsolidatedMember | 844341000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant_NonConsolidatedMember | 667706000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant_NonConsolidatedMember | 436811000 | JPY |
| Directors compensations sga | Prior1YTDDuration_NonConsolidatedMember | 43600000 | JPY |
| Directors compensations sga | CurrentYTDDuration_NonConsolidatedMember | 40249000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)四国財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-11-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第14期第２四半期(自 2023年７月１日 至 2023年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ 株式会社 | |
| Company name in english cover page | FilingDateInstant | Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ，Ｉｎｃ． | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 江島 淸 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)徳島県徳島市川内町宮島錦野37番地の５ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)088-637-1055(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役 管理部門担当 黒滝 健一 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町３丁目11番５号日本橋ライフサイエンスビルディング２ ６階 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-6231-1278 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役 管理部門担当 黒滝 健一 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E34318 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45980 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ 株式会社 | |
| Filer name in english | FilingDateInstant | Delta-Fly Pharma,Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | false | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Current fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Current period end date | FilingDateInstant | 2023-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Comparative period end date | FilingDateInstant | 2022-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2023-03-31 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |